The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.

Abstract: Binding members for potassium channel Kv1.3 and their use in medicine, including for treatment of autoimmune conditions, metabolic disorders and obesity. Binding members comprise a fusion protein containing a Kv1.3-binding peptide, e.g., HsTx, ShK or KTX (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), paired with a partner domain (e.g., antibody variable domain).

A polyelectrolyte-surfactant complex, a method of removing a toxic substance from contaminated soil or contaminated groundwater using a polyelectrolyte-surfactant complex and a method of making a polyelectrolyte-surfactant complex. The polyelectrolyte-surfactant complex is made from a complexated recombinant intrinsically disordered protein that has been electrostatically conjugated to an anionic surfactant to provide enhanced liquid-liquid phase separation properties.

The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control, By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.

The present invention relates to the field of structural biology and drug discovery. More specifically, the present invention relates to novel fusion proteins, their uses and methods in three-dimensional structural analysis of macromolecules, such as X-ray crystallography and high-resolution Cryo-EM, and their use in structure-based drug design and screening, and as pharmacological tools. Even more specifically, the invention relates to a functional fusion of a toxin and a scaffold protein wherein the folded scaffold protein interrupts the topology of the toxin by insertion in an exposed β-turn of a β-strand-containing domain of said toxin to form a rigid fusion protein that retains its high affinity target binding capacity.

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.

Disclosed herein is a novel phenomenon to create a nano-confined, dopant-free, electron spin-dependent fluorescence (SDF) in spider silk by fundamentally transforming its local molecular structure with femtosecond-pulses (206), having fluence below an ablation threshold. Electron-spin dependence of the fluorescent patterns created on the silk sample are confirmed by measuring the fluorescence intensity at different microwave frequencies. The fluorescent intensity exhibits microwave magnetic resonances at 2.88 GHz and 1.44 GHz at room-temperature. The SDF in laser-transformed silk can thereby enable a new-class of tough yet elastic silk-based quantum sensor and hybrid nano-mechanical ultrasensitive cantilevers on a micro-chip. X-ray diffraction (XRD), Raman-spectroscopy, direct atomistic imaging with high-resolution transmission electron microscopy (HR-TEM) and model-building studies are carried out to exhibit the change in the molecular structure and unveil creation of crown-ring like structure in nanocrystals of fluorescent silk with localized electrons possessing mid-gap states.

The present invention provides for concentrated aqueous silk fibroin solutions and an all-aqueous mode for preparation of concentrated aqueous fibroin solutions that avoids the use of organic solvents, direct additives, or harsh chemicals. The invention further provides for the use of these solutions in production of materials, e.g., fibers, films, foams, meshes, scaffolds and hydrogels.

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.